Sector News

Luminex Completes CEO Transition

September 10, 2015
Life sciences

(BUSINESS WIRE) – Luminex Trading & Analytics LLC, a buy-side owned trading venue which seeks to deliver the benefits of low cost and more efficient trading, today announced that it has completed its previously announced CEO transition, and has expanded its leadership team with the appointments of four key executives. Luminex plans to open for trading in the fourth quarter of 2015 as a new, independent platform for investment managers with a long term focus to trade large blocks of stock with other investment managers.

Jonathan A. Clark has assumed the role of permanent CEO effective today replacing interim CEO Michael S. Cashel who will return to his position of SVP of Fidelity Trading Ventures. Mr. Cashel will continue to serve in an advisory capacity to Luminex, as needed.

“On behalf of the Luminex Board I would like to thank Mike for his tremendous efforts in establishing Luminex and positioning the company for a successful launch,” said Kevin Cronin, Luminex Board member and Global Head of Trading of Invesco Advisers, Inc. “With the appointments of Jon and his team, we have delivered on our commitment to bring independent leadership to Luminex and we look forward to the opportunity to provide the buy-side with an efficient and low cost trading platform as we progress toward launch.”

Jonathan A. Clark, CEO of Luminex, commented, “I am excited to assume the role of CEO and look forward to bringing the unique benefits of the Luminex platform to our clients. Client interest is robust as the prospect of a well-capitalized, independent platform which provides a low-cost, transparent solution for block trading clearly resonates with investors. I am confident in the tremendous talent we have added to our leadership team and look forward to a successful launch of trading in the fourth quarter.”

In addition to the CEO transition, Luminex also announced the appointment of the following key leaders:

Brian Williamson has been appointed Head of Sales and will be responsible for working directly with Luminex’s clients to ensure a positive customer experience while continuing to build the Luminex client base. Mr. Williams has extensive experience in trading and relationship management including with Liquidnet, where he served as a Senior Global Relationship Manager, and with The Boston Company, where he was Vice President for Equity Trading.
James C. Dolan, has been appointed Chief Compliance Officer with responsibility for Luminex’s regulatory and market compliance, as well as the further development of the firm’s internal compliance infrastructure. Mr. Dolan has an extensive background in top compliance roles, including nearly twenty years with NASD (FINRA), where he led the insider trading investigations program, among other roles. Prior to joining Luminex, Mr. Dolan was at Fidelity since 2007, most recently serving as Vice President of Compliance for Fidelity Institutional, supporting the Prime Brokerage Services, Securities Finance, Fixed Income, International Equity, and Forex businesses of Fidelity Capital Markets.

David Hagen has been appointed as Head of Product where he will oversee Luminex’s product development efforts and will chair the Luminex Advisory Council. Prior to joining Luminex, Mr. Hagen was a Director at Pico Quantitative Trading, focused on expanding Pico’s services to the Institutional trading community. His previous experience includes nine years at Linedata as both Director of Strategic Accounts & Trading and VP Global Trading Technologies, and at the Boston Stock Exchange, where he held the roles of specialist and Head Trader.

Daniel J. Consigli has joined Luminex as the firm’s controller. Mr. Consigli has over 20 years of finance and operational experience at financial institutions. He most recently served as a divisional financial officer at IDB Bank and previously held finance, operational and consulting roles at J.P. Morgan Chase, Resources Global, Pioneer Investment Management and Fidelity Investments.

Source: Luminex

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.